ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 301 for:    complementary and alternative medicine

The Application of Evidence-Based Chinese Complementary and Alternative Medicine (CAM) in Hospice Palliative Care in Taiwan

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02663063
Recruitment Status : Unknown
Verified January 2016 by Taipei Veterans General Hospital, Taiwan.
Recruitment status was:  Enrolling by invitation
First Posted : January 26, 2016
Last Update Posted : February 2, 2016
Sponsor:
Information provided by (Responsible Party):
Taipei Veterans General Hospital, Taiwan

January 21, 2016
January 26, 2016
February 2, 2016
December 2015
October 2016   (Final data collection date for primary outcome measure)
Symptom severity score [ Time Frame: One week after treatment ]
Questionnaire for evaluating the severity of symptoms
Same as current
Complete list of historical versions of study NCT02663063 on ClinicalTrials.gov Archive Site
Quality of life [ Time Frame: One week after treatment ]
Questionnaire for evaluating quality of life
Same as current
Not Provided
Not Provided
 
The Application of Evidence-Based Chinese Complementary and Alternative Medicine (CAM) in Hospice Palliative Care in Taiwan
The Application of Evidence-Based Chinese Complementary and Alternative Medicine (CAM) in Hospice Palliative Care in Taiwan-The Second and Third Year Project.
The study aims to explore the effects of silver spike point (SSP) treatment on common symptoms including pain, breathlessness, nausea/vomiting, dry mouth etc. of terminal cancer patients.
The study aims to explore the effects of silver spike point treatment on common symptoms including pain, breathlessness, nausea/vomiting, dry mouth etc. of terminal cancer patients. We will conducted a pilot study to evaluate the effects on different symptoms and then a prospective study will be conducted after validation of major effects.
Interventional
Not Applicable
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Supportive Care
Cancer
Device: SSP treatment
SSP treatment 5 times a week
  • Experimental: SSP treatment group
    Case on SSP treatment
    Intervention: Device: SSP treatment
  • Sham Comparator: Non-SSP treatment group
    Sham SSP treatment
    Intervention: Device: SSP treatment

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
494
Same as current
October 2016
October 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Cancer patients
  • Competent with clear consciousness
  • With symptoms of pain, breathlessness, nause/vomiting, dry mouth, generalized discomfort
  • Expected life span of at least 1 week

Exclusion Criteria:

  • With implanted devices
  • Not having clear consciousness
  • Expected life span less than 1 week
  • Foreigner
Sexes Eligible for Study: All
20 Years to 90 Years   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
Taiwan
 
 
NCT02663063
2015-10-005A
Yes
Not Provided
Plan to Share IPD: Undecided
Plan Description: Undecided
Taipei Veterans General Hospital, Taiwan
Taipei Veterans General Hospital, Taiwan
Not Provided
Principal Investigator: Shinn-Jang Hwang, MD Taipei Veterans General Hospital, Taipei, Taiwan
Taipei Veterans General Hospital, Taiwan
January 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP